Healthcare Global Enterprises Ltd Q4 FY2025 Concall Summary

Key Takeaways

• Core portfolio delivered 17% revenue growth: HCG ex-Milann grew revenue and EBITDA 17% YoY, driven by established centers, emerging hubs, and a sharp South Mumbai recovery.
• PAT declined on investment-led costs: Depreciation and interest rose from INR275 crores in ROU creation, INR400 crores in fixed assets, and ~INR250 crores in net debt, pulling PAT down; normalization is expected as new capacity scales.
• KKR replaces CVC as anchor investor: The sponsor change is underway, with management citing a long-term vision alignment and a potential primary equity infusion decision in coming months.
• Margin mix is shifting toward medical oncology: The modality is the least profitable but highly return-accretive; management expects operating leverage from scaling emerging centers to more than compensate.
• What to watch next quarter: Whether the Vizag integration margin recovers toward the 25–30% target, the pace of Bangladesh patient-flow normalization, and any decision on primary equity and the Milann divestment.

Core Portfolio Performance

• Established centers momentum: Revenue grew 22% YoY and EBITDA 15%, reflecting steady upward trajectory across mature hubs.
• Emerging centers operating leverage: Revenue rose 32% and EBITDA 44%, demonstrating the model’s ability to scale profitability as these Tier-1 hubs ramp up.
• South Mumbai turnaround: The center posted 37% YoY growth, recovering from a prior drop in international patient flow.
• Kolkata traction: Delivered 22% growth, fuelled by rising local awareness, improved clinical offerings, and better operational alignment.
• LINAC utilization steady at 60%: Held flat in Q4 FY25 even after adding two LINACs via the MGM Hospital acquisition over the prior twelve months.
• Digital revenue doubled: Revenue from website and social media channels doubled over the past year, driven by localized search engine optimization.

Raj Gore: "what digital platform gives us, is an ability to make patients easier to find us rather than we trying to find these 0.2 crore patients among 140 crores population."

Margin Dynamics

• Medical oncology mix pressure: EBITDA margin declined ~40–50 bps YoY primarily because of higher contribution from medical oncology, the least profitable modality; management expects higher operating leverage from scaling centers to more than compensate.
• Emerging center margin bridge: As emerging centers inch closer to established centers’ EBITDA margins, overall margins are expected to improve.
• Vizag integration drag: MGM Vizag had a 35% margin in an earlier year but is now in transition; post-acquisition, some operating costs identified during diligence were corrected, and Odisha’s government scheme withdrawal from non-Odisha states hit Vizag, which was its largest beneficiary treating Odisha patients.
• Vizag steady-state target: Management expects normalized EBITDA margin in the 25% to 30% range as revenue scales.
• Receivables normalization: Receivables rose YoY due to state elections and a code of conduct that pushed collections into April, plus newly acquired Vizag receivables; March had the highest-ever collection, and 105–107 days is the expected new normal.

B.S. Ajaikumar: "But is it good to say as the emerging centers also rack up, our margin, as we always indicated, will be in the low 20s. That is our initial goal."

Expansion & Capacity Build-Out

• Ahmedabad flagship inaugurated: A 189-bed facility with 9 OTs, 34 ICU beds, 22 day-care beds, and 6 dedicated bone marrow transplant units; projected to drive a 30–40% increase in patient footfall at the center.
• Bangalore expansion: Two new hospitals announced: North Bangalore (commencing second half of FY26) and Whitefield (a strategic extension of an existing center of excellence).
• 900+ beds over three years: The network aims to operationalize over 900 beds within three years, including 200 currently non-operational beds and an additional 600–700 beds over the next two to three years.
• Five LINACs added in FY25: Deployed across multiple centers using a pay-per-use model to remain asset-light.
• Orbitrap Astral Mass Spectrometer: HCG is one of the first acquirers globally of this advanced high-resolution mass spectrometry platform from Thermo Fisher Scientific.
• Capex trajectory: FY26 capex is INR286 crores, expected to reduce going forward toward a maintenance level of ~INR100 crores plus some growth capex; incremental growth capex will be disclosed as plans firm up.

International & Competitive Position

• Bangladesh patient flow suppressed: India reduced medical visas for Bangladeshi patients due to geopolitical issues, impacting all Indian hospital players; international revenue is around 3–4% of total, and management expects the suppression to continue for a few months but does not expect it to impact overall revenue growth this year, as domestic channels compensate.
• CCK Cancer Center (Nairobi) progressing: New radiation equipment and a PET scan installed; the Board discussed a concept node to further improve the international opportunity in Africa, with updates expected in coming quarters alongside the new investor.
• Market leadership maintained: Management states HCG has not lost market leadership in any location in the last three to four years despite competition; in Bangalore, market share has grown over four years even as multiple multi-specialty players entered oncology.
• Tier-2 profitability despite lower ARPOB: The business model demonstrates similar profitability and return in Tier-2 markets compared to metros, even with lower ARPOB.

B.S. Ajaikumar: "when you talk about the competitive landscape, we feel honestly, they should be worried about us, not worried about them because the way we are expanding, putting together the quality of excellence, the quality we have today is unmatched. And I trained in Houston, MD Anderson, I can say we are equal to that very clearly."

Capital Structure & Corporate Actions

• KKR replacing CVC: CVC is diluting its stake, and KKR is coming in as the new investor; formalities are being completed, and management emphasized a long-term vision alignment with the incoming shareholder.
• Primary equity possibility: Once KKR is in place, the company will evaluate the possibility of primary equity infusion; a decision is expected in the coming few months.
• Primary infusion impact on PAT: Depending on the quantum infused and any short-term allocation toward debt reduction, interest costs would decline and PAT would improve; as profitability improves, headroom would be created to leverage appropriately for future growth.
• Milann divestment proposal: A proposal to divest the Milann fertility business is being put forward and has been discussed with the new investor; management expects it to happen this fiscal year.
• Transaction bonus to employees: Management declined to comment on the rationale or coverage of a transaction bonus paid by shareholders to employees, stating all relevant information was disclosed at CVC and directing questions to CVC.

B.S. Ajaikumar: "we have CVC is diluting in place KKR is coming in, formalities are being completed. We look with the new investors for a long-term vision for HCG, which is very, very important to us."

Guidance & Commitments

Key Metrics